Effects of dexrazoxane and amifostine on evolution of Doxorubicin cardiomyopathy in vivo.
Doxorubicin is one of the most active drugs in oncology, with cardiotoxicity as a serious side effect of its application. The aim of this study was to investigate dexrazoxane and amifostine impact on the evolution of myocardial changes induced by doxorubicin. BalbC female mice were treated with doxorubicin only (10 mg/kg, single intravenous push), or with dexrazoxane (200 mg/kg, intraperitoneal [ip]) or amifostine (200 mg/kg, ip) 60 mins or 30 mins prior to treatment with doxorubicin, respectively. Blood sampling for determination of conventional serum-marker activity was performed 48 hrs later. The grade of histopathology changes was evaluated by light microscopy 1.5 and 3 months after treatments using the Billingham scoring method. Control groups consisted of nontreated mice. After doxorubicin-only treatment, the grade of heart tissue damage was found to increase in the period between 1.5 and 3 months. A similar but less intense progression was also detected in amifostine-pretreated animals, with significant difference among median Billingham scores between the two time points. The pretreatment with dexrazoxane suspended expansion of tissue lesions in time. Changes in serum enzyme activity revealed two correlations: the greater reduction in alpha-hydroxybutyrate dehydrogenase (alpha-HBDH) leakage is associated with a lower percentage of damaged tissue, and the creatine kinase to alpha-HBDH percent of difference ratio being greater than one is correlated with limited spreading of pathological lesions. Our results indicate that the development of doxorubicin-induced heart failure is based on a slow and persistent expansion of pathological process even long after the completion of the treatment. Dexrazoxane has proved to be successful and superior over amifostine against such an evolution of doxorubicin cardiomyopathy.
Department of Experimental Oncology, Institute for Oncology and Radiology of Serbia, Pasterova 14, Belgrade, Serbia. zanab@bitsyu.net
Snezana K
SK
Bjelogrlic
Jelena
J
Radic
Sinisa
S
Radulovic
Milan
M
Jokanovic
Viktor
V
Jovic
D004999:Amifostine / Q000494:pharmacology*; D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects* / Q000494:pharmacology; D009202:Cardiomyopathies / Q000139:chemically induced / Q000201:enzymology / Q000473:pathology / Q000517:prevention & control; D002317:Cardiovascular Agents / Q000494:pharmacology*; D003402:Creatine Kinase; D004317:Doxorubicin / Q000009:adverse effects* / Q000494:pharmacology; D005260:Female; D006884:Hydroxybutyrate Dehydrogenase / Q000097:blood; D051379:Mice; D008807:Mice, Inbred BALB C; D009206:Myocardium / Q000201:enzymology / Q000473:pathology; D011837:Radiation-Protective Agents / Q000494:pharmacology*; D011929:Razoxane / Q000494:pharmacology*; D013997:Time Factors
D000903:Antibiotics, Antineoplastic; D002317:Cardiovascular Agents; D011837:Radiation-Protective Agents; D011929:Razoxane; D004317:Doxorubicin; C035749:2-hydroxybutyrate dehydrogenase; D006884:Hydroxybutyrate Dehydrogenase; D003402:Creatine Kinase; D004999:Amifostine